Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats

British Journal of Pharmacology

Volumn 164, Issue 1, 2011, Pages 106-118

  Kim, Byung Hak ^a   Kim, Myunghwan ^b   Yin, Chang Hong ^a   Jee, Jun Goo ^c   Sandoval, Claudio ^a   Lee, Hyejung ^b   Bach, Erika A ^d   Hahm, Dae Hyun ^b   Baeg, Gyeong Hun ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Kyung Hee University   (South Korea)

^c TOKYO METROPOLITAN UNIVERSITY   (Japan)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

inflammation; JAK; small molecule inhibitor, berberine, IL 2, IL 3; STAT

Indexed keywords

BERBERINE; CELECOXIB; INTERLEUKIN 2; JANUS KINASE 3; NSC 163088; PREDNISOLONE; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG PROTEIN BINDING; DRUG STRUCTURE; EDEMA; HIGH THROUGHPUT SCREENING; HYPERALGESIA; KNEE ARTHRITIS; MALE; MOLECULAR DOCKING; MONARTHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RAT; SYNOVITIS; SYNOVIUM; UPREGULATION;

ANIMALS; ARTHRITIS; BERBERINE; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; INFLAMMATION; INTERLEUKIN-2; JANUS KINASE 3; MALE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 79961239419     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01353.x     Document Type: Article

References (45)

1. Bhadra K, Kumar GS, (2010). Therapeutic potential of nucleic acid-binding isoquinoline alkaloids: binding aspects and implications for drug design. Med Res Rev [Epub ahead of print].
2. Bharti AC, Donato N, Aggarwal BB, (2003). Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171: 3863-3871. (Pubitemid 37254592)
3. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM, (2003). Discovery of JSI-124 (cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279. (Pubitemid 36348705)
4. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al,. (2003). Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 302: 875-878. (Pubitemid 37339629)
5. Choi YL, Kaneda R, Wada T, Fujiwara S, Sod M, Watanabe H, et al,. (2007). Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res 31: 203-209. (Pubitemid 44854191)
6. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al,. (2010). Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 69: 413-416.
7. David M, Petricoin E 3rd, Larner AC, (1996). Activation of protein kinase A inhibits interferon induction of the Jak/Stat pathway in U266 cells. J Biol Chem 271: 4585-4588. (Pubitemid 26074931)
8. Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, et al,. (2001). Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol 13: 363-373. (Pubitemid 32537710)
9. Germolec DR, Frawley RP, Evans E, (2010). Markers of inflammation. Methods Mol Biol 598: 53-73.
10. Ghoreschi K, Laurence A, O'Shea JJ, (2009). Janus kinases in immune cell signaling. Immunol Rev 228: 273-287.
11. Imanshahidi M, Hosseinzadeh H, (2008). Pharmacological and therapeutic effects of berberis vulgaris and its active constituent, berberine. Phytother Res 22: 999-1012.
12. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, et al,. (2009). Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296: E955-E964.
13. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al,. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
14. Kasperkovitz P, Verbeet N, Smeets T, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, et al,. (2004). Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 63: 233-239. (Pubitemid 38250663)
15. Kim BH, Jee JG, Yin CH, Sandoval C, Jayabose S, Kitamura D, et al,. (2010). NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3. Mol Cancer 9: 36.
16. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW, (2002). Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-24. (Pubitemid 34246317)
17. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al,. (2009). The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60: 1895-1905.
18. Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, Changelian P, (2008). The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 582: 154-161.
19. Kuo CL, Chi CW, Liu TY, (2004). The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137.
20. Lee IA, Hyun YJ, Kim DH, (2010). Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. Eur J Pharmacol 648: 162-170.
21. Lin TH, Hegen M, Quadros E, Nickerson-Nutter CL, Appell KC, Cole AG, et al,. (2010). Selective functional inhibition of JAK3 kinase is sufficient for efficacy in collagen induced arthritis in mice. Arthritis Rheum 62: 2283-2293.
22. Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, et al,. (2008). LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 7: 1176-1184.
23. Liu Y, Yu H, Zhang C, Cheng Y, Hu L, Meng X, et al,. (2008). Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur J Cancer 44: 2425-2432.
24. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al,. (1995). Mutations of jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377: 65-68.
25. Malaviya R, Zhu D, Dibirdik I, Uckun FM, (1999). Targeting janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 274: 27028-27038. (Pubitemid 129520227)
26. Malemud CJ, (2010). Suppression of autoimmune arthritis by small molecule inhibitors of the JAK/STAT pathway. Pharmaceuticals 3: 1446-1455.
27. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P, (2008). Cartilage preservation by inhibition of janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 10: R14.
28. O'Shea JJ, Gadina M, Schreiber RD, (2002). Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 (Suppl.): S121-S131. (Pubitemid 34457857)
29. Papageorgiou AC, Wikman LE, (2004). Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol Sci 25: 558-562. (Pubitemid 39371145)
30. van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet N, Smeets T, Kraan M, et al,. (2003). Rheumatoid arthritis is a heterogenous disease. Evidence for differences in the activation of the STAT1 pathway between tissues. Arthritis Rheum 48: 2132-2145. (Pubitemid 36959193)
31. Puck JM, Deschenes SM, Porter JC, Dutra AS, Brown CJ, Willard HF, et al,. (1993). The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 2: 1099-1104. (Pubitemid 23244985)
32. Rochman Y, Spolski R, Leonard WJ, (2009). New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9: 480-490.
33. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al,. (1995). Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270: 797-800.
34. Schaible HG, Freudenberger U, Neugebauer V, Stiller RU, (1994). Intraspinal release of immunoreactive calcitonin gene-related peptide during development of inflammation in the joint in vivo-a study with antibody microprobes in cat and rat. Neuroscience 62: 1293-1305. (Pubitemid 24335619)
35. Sluka KA, Westlund KN, (1993). Behavioral and immunohistochemical changes in an experimental arthritis model in rats. Pain 55: 367-377. (Pubitemid 23350583)
36. Sun Y, Xun K, Wang Y, Chen X, (2009). A systematic review of the anticancer properties of berberine, a natural product from chinese herbs. Anticancer Drugs 20: 757-769.
37. Verstovsek S, (2009). Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program Book 2009: 636-642.
38. Walker JG, Smith MD, (2005). The jak-STAT pathway in rheumatoid arthritis. J Rheumatol 32: 1650-1653. (Pubitemid 41324798)
39. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al,. (2006a). Changes in synovial tissue jak-stat expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 65: 1558-1564. (Pubitemid 44799665)
40. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al,. (2006b). Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 65: 149-156. (Pubitemid 43131986)
41. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al,. (2007). Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 66: 992-999. (Pubitemid 47122309)
42. Wang JM, Yang Z, Xu MG, Chen L, Wang Y, Su C, et al,. (2009). Berberine-induced decline in circulating CD31+/CD42- microparticles is associated with improvement of endothelial function in humans. Eur J Pharmacol 614: 77-83.
43. West K, (2009). CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 10: 491-504.
44. Wu X, Li Q, Xin H, Yu A, Zhong M, (2005). Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 61: 567-572. (Pubitemid 41414240)
45. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ, (2004). The janus kinases (jaks). Genome Biol 5: 253.